> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rapport Therapeutics Prices $200 Million Share Sale At $21, Below Tuesday's $27.54 Price
- URL: https://www.bullished.co/rapport-therapeutics-prices-200-million-share-sale-at-21-below-tuesdays-27-54-price-8d01d92e/
- Published: 2026-10-28T11:16:15.000Z
- Updated: 2026-10-29T16:59:57.000Z
- Description: The biotech also priced $150 million of 2.25% convertible notes and a private placement, and says the money funds operations through the end of 2029.
- Author: Matteo Parrino
- Tags: SEC Filings, RAPP, Industry: Healthcare, Topic: Capital Raising

[Rapport Therapeutics](https://www.bullished.co/tag/rapp/), a clinical-stage biotech developing medicines for neurological and psychiatric disorders, priced a [$200.0 million stock offering](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526435057/d59324dfwp.htm?ref=bullished.co) at $21.00 a share on Wednesday, a 23.7% discount to the $27.54 last reported sale price on October 27\. It paired the sale with $150 million of convertible notes and a private placement.

## Three deals priced at once

The public offering covers [8,333,334 common shares](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526435057/d59324dfwp.htm?ref=bullished.co), plus pre-funded warrants (shares with a nominal $0.001 exercise price) for up to 1,190,476 shares. Underwriters hold an option to buy additional shares, which would lift the total to 9,761,905 shares and the offering to about $230.0 million. The underwriting discount is $1.26 a share, about $12.0 million in all.

A single investor agreed to buy 1,428,571 shares at $21.00 in a concurrent private placement. Rapport estimates net proceeds from the share offering and the private placement at about $215.7 million, or about $243.9 million if the underwriters' option is exercised in full.

The stock offering and notes are set to settle on October 30.

## Notes convert at $26.7750

The $150,000,000 of 2.25% [convertible senior notes](https://www.nasdaq.com/press-release/rapport-announces-proposed-public-offerings-common-stock-and-convertible-notes-well?ref=bullished.co) due December 1, 2032 are senior unsecured. The initial conversion price is about $26.7750 a share, roughly 27.50% above the $21.00 offering price. Underwriters can buy up to an additional $22,500,000 of notes, and net proceeds are estimated at about $145.0 million.

Rapport agreed to settle conversions in physical shares and to cap any holder's conversion at a beneficial ownership limit of 19.99% of shares outstanding. It can redeem the notes for cash on or after the later of December 6, 2030 and 60 days after reported topline data from its planned RAP-219 trials, if the stock has traded at least 130% of the conversion price for 20 of 30 trading days.

## Money for RAP-219 trials

Rapport has no products on the market. Its lead candidate, RAP-219, is being studied in focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. The company said it will use proceeds "primarily to fund our ongoing and planned clinical trials advancing RAP-219, for other research and development, and for working capital and general corporate purposes."

Rapport said the proceeds, with its existing cash and short-term investments, should fund operations through the end of 2029, an estimate it cautions rests on assumptions that may prove wrong. Morgan Stanley, Leerink Partners and Evercore lead the book-running group, with BTIG and Citizens JMP also joint managers on the stock sale.

Rapport's market value stood at $1.3 billion at the $27.54 price before the pricing.

Learn

- [How A Secondary Offering Affects A Stock's Price →](https://www.bullished.co/learn/how-secondary-offering-affects-stock-price/)  
A secondary offering is usually priced below the last close, which sets up pressure on the stock. See how it works with real October offerings and what to check.
- [How To Calculate Stock Dilution: The Formula, Worked Through Real Offerings →](https://www.bullished.co/learn/how-to-calculate-stock-dilution/)  
Stock dilution is new shares divided by shares outstanding after the sale. See the formula worked on real offerings and where to find the counts in a filing.

### Sources

- [Form FWP — Rapport Therapeutics, Inc. (RAPP)](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526435057/d59324dfwp.htm?ref=bullished.co) — SEC EDGAR
- [Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement | Nasdaq](https://www.nasdaq.com/press-release/rapport-announces-proposed-public-offerings-common-stock-and-convertible-notes-well?ref=bullished.co) — nasdaq.com
- [Rapport Announces Pricing of Underwritten Offerings of](https://www.globenewswire.com/news-release/2026/10/28/3389940/0/en/rapport-announces-pricing-of-underwritten-offerings-of-common-stock-and-pre-funded-warrants-and-convertible-notes-and-concurrent-private-placement.html?ref=bullished.co) — globenewswire.com
- [Rapport Announces Proposed Public Offerings of Common Stock](https://www.globenewswire.com/news-release/2026/10/27/3389673/0/en/rapport-announces-proposed-public-offerings-of-common-stock-and-convertible-notes-as-well-as-concurrent-private-placement.html?ref=bullished.co) — globenewswire.com
- [Rapport Announces Proposed Public Offerings of Common Stock](https://rss.globenewswire.com/news-release/2026/10/27/3389673/0/en/rapport-announces-proposed-public-offerings-of-common-stock-and-convertible-notes-as-well-as-concurrent-private-placement.html?ref=bullished.co) — rss.globenewswire.com
- [Rapport Announces Proposed Public Offerings of Common Stock](https://www.globenewswire.com/de/news-release/2026/10/27/3389673/0/en/rapport-announces-proposed-public-offerings-of-common-stock-and-convertible-notes-as-well-as-concurrent-private-placement.html?ref=bullished.co) — globenewswire.com

### More on Rapport Therapeutics

- [Rapport's Bipolar Mania Drug Beat Placebo By 3.1 Points, But Twice As Many Quit Treatment](https://www.bullished.co/rapports-bipolar-mania-drug-beat-placebo-by-3-1-points-but-twice-as-many-quit-treatment-f4fda96c/)

[All Rapport Therapeutics (RAPP) coverage →](https://www.bullished.co/tag/rapp/)